FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
21/11/2023
Voltar para busca
Dado oficial do USPTO
BERGENBIO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
54
Atualização mais recente
21/11/2023
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 42
Data de depósito
22/10/2021
Data de registro
01/08/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/08/2023
Última transação
01/08/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
63
Localização do titular
NO
Examinador
BARRETT, LEAH N
Unidade examinadora
L60
Localização atual
TMEG LAW OFFICE 106
Descrição da marca
The mark consists of the stylized wording "BERGENBIO" to the right of a design of 6 shaded circles and one outlined hexagon arranged in an overall hexagonal shape.
Titulares e representantes
Titulares
B. A. (pessoa física)
Representantes
James M. Theo Dinsmore & Shohl LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical preparationschemical compoundsbiochemical preparations and biologic compounds for scientific or industrial purposesfor use in laboratories or in research; chemical preparationschemical compoundsbiochemical preparations and biologic compounds for analytical and diagnostic purposes in laboratory use; chemical preparationschemical compoundsbiochemical preparations and biologic compounds for the experimental production of drugspharmaceutical products and biotechnological preparations; chemical preparationschemical compoundsbiochemical preparations and biologic compounds for use in the development and manufacture of diagnostic products and servicesdrugs and pharmaceutical productsthe diagnosis and treatment of cancersincluding lung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; chemical preparationschemical compoundsbiochemical preparations and biologic compounds for use in the development and manufacture of drugs and pharmaceutical productsdrugs and pharmaceutical products that target axlakt3 or other genesproteinskinases and enzymes; active chemical and biochemical ingredients and components for use in the development and manufacture of diagnostic products and servicesdrugs and pharmaceutical productsfor the diagnosis and treatment of cancersincluding lung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; antibodiessmall molecules and proteins for scientific or industrial purposesfor use in laboratories or in research; antibodiessmall molecules and proteins for use in the development and manufacture of diagnostic products and servicesdrugs and pharmaceutical productsfor the diagnosis and treatment of cancersincluding lung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; antibodiessmall molecules and proteins for use in the development and manufacture of drugs and pharmaceutical productsdrugs and pharmaceutical products that target axlakt3 or other genesproteinskinases and enzymes; antibodiesanti-axl antibodiessmall moleculessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins for scientific or industrial purposesfor use in laboratories or in research; antibodiesanti-axl antibodiessmall moleculessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of diagnostic products and servicesdrugs and pharmaceutical productsfor the diagnosis and treatment of cancersincluding lung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; antibodiesanti-axl antibodiessmall moleculessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of drugs and pharmaceutical productsdrugs and pharmaceutical products that target axlakt3 or other genesproteinskinases and enzymes; proteins for use in kinase inhibiting technologyfor scientific purposes
Classe 5
Drugs and pharmaceutical products for medical purposesmedications for the treatment of cancer and severe respiratory infections; drugs and pharmaceutical products for medical purposes incorporating antibodiesanti-axl antibodiessmall moleculessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitorsselective inhibitors of cell surface proteinsmedications for the treatment of cancer and severe respiratory infections; drugs and pharmaceutical products for medical purposesfor use in oncology and for the treatment of cancerslung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; drugs and pharmaceutical products that target axlakt3 or other genesproteinskinases and enzymes; chemical preparationschemical compoundsbiochemical preparations and biologic compounds for medical purposes; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for medical laboratory analysis; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease testingthe testing for lung cancerleukaemiaaggressive cancersimmune evasive cancersmetastatic cancers and severe respiratory infections; antibodiessmall molecules and proteins for medical purposes; antibodiesanti-axl antibodiessmall moleculessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins for medical purposes; protein synthesis inhibitors for medical purposes
Classe 42
Drug discovery and pharmaceutical drug development services; scientific research services; research and development services in the fields of oncology and immunology; scientific research services related to the role of axl and related kinase signalling in disease; scientific research services related to axl biology and its role in mediating aggressive disease; scientific research services related to biomarker discovery; scientific research services related to the development of diagnostic products and servicesin the field of treatment of cancersincluding lung cancerleukaemiaaggressive cancersimmune evasive cancers and metastatic cancers; scientific research services related to improving the efficacy of chemotherapytargeted cancer therapy and immunooncology drugs; research and development services in the field of antibodiessmall molecules and proteins; conducting and providing research and development services for others in the field of antibody and small molecule technology; medical and biotechnology research services; researchdevelopment and engineering of antibodiessmall molecules and proteinsanti-axl antibodiessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins; laboratory research services relating to the production of antibodiessmall molecules and proteinsanti-axl antibodiessmall molecules that inhibit axl kinaseselective inhibitorsselective axl inhibitorsselective axl kinase inhibitors and selective inhibitors of cell surface proteins; researching and developing the use of antibodiessmall molecules and proteins for the treatment of patients; informationconsultancy and advisory services related to the aforesaid services
Publicações
Histórico de despachos e eventos da marca no USPTO.
54 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/11/2023
FIMP
FINAL DISPOSITION PROCESSED
01/11/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/11/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/08/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
01/08/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
26/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/06/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
07/06/2023
GPNX
NOTIFICATION PROCESSED BY IB
17/05/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/05/2023
PUBO
PUBLISHED FOR OPPOSITION
16/05/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
26/04/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
26/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/04/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/04/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/04/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/04/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
28/03/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
28/03/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
28/03/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
28/03/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
28/03/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
28/02/2023
GNRT
NON-FINAL ACTION E-MAILED
28/02/2023
CNRT
NON-FINAL ACTION WRITTEN
28/02/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
05/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/01/2023
RFNT
REFUSAL PROCESSED BY IB
24/01/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/01/2023
RFRR
REFUSAL PROCESSED BY MPU
04/01/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/10/2022
CNRT
NON-FINAL ACTION WRITTEN
17/10/2022
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
11/10/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/10/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/10/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/10/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/10/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/08/2022
CNRT
NON-FINAL ACTION WRITTEN
08/08/2022
DOCK
ASSIGNED TO EXAMINER
01/08/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/05/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/05/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/05/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/05/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/05/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/03/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/01/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/01/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/01/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BERGENBIO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.